advertisement
Sonoda KH 27
Showing records 1 to 25 |
Display all abstracts from Sonoda KH95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurityArima M
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and CytomegalovirusTerada Y; Kaburaki T
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurityInoue H; Nakao S
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and CytomegalovirusTakase H; Goto H
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurityMisumi A; Suzuki M
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and CytomegalovirusNakano S; Inoue Y
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurityMatsushita I
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and CytomegalovirusMaruyama K
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurityAraki S; Yamashiro C
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and CytomegalovirusMiyata K; Namba K
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurityTakahashi K
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and CytomegalovirusNamba K; Sonoda KH
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurityOchiai M
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and CytomegalovirusKaneko Y
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurityYoshida N
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and CytomegalovirusNumaga J
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurityHirose M; Kishimoto J
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and CytomegalovirusFukushima M; Horiguchi N
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurityTodaka K; Hasegawa S
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and CytomegalovirusIde M; Ehara F
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurityKimura K; Kusuhara K
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and CytomegalovirusMiyazaki D; Miyazaki D
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurityKondo H
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and CytomegalovirusHasegawa E
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurityOhga S
BMJ open 2021; 11: e047003
Issue 22-2
Change Issue
advertisement